Loading...
Baseline characteristics and temporal differences in acarbose cardiovascular evaluation (ACE) trial participants
Theodorakis, Michael J. Coleman, Ruth L. Feng, Huimei Chan, Juliana Chiasson, Jean Louis Ge, Junbo Gerstein, Hertzel C. Huo, Yong Lang, Zhihui McMurray, John
Theodorakis, Michael J.
Coleman, Ruth L.
Feng, Huimei
Chan, Juliana
Chiasson, Jean Louis
Ge, Junbo
Gerstein, Hertzel C.
Huo, Yong
Lang, Zhihui
McMurray, John
Abstract
The ACE trial is examining whether acarbose, an insulin-sparing postprandial glucose-lowering agent, can reduce cardiovascular (CV) events in patients who have coronary heart disease (CHD) and impaired glucose tolerance (IGT), with prevention of type 2 diabetes (T2D) as a secondary outcome.1., 2. This update report evaluates the impact of the protocol-driven 4-week CV risk management optimization strategy during the run-in period, lists participant baseline characteristics, and examines whether temporal differences occurred during the 7-year recruitment period.
Keywords
Date
2018
Type
Journal article
Journal
American Heart Journal
Book
Volume
199
Issue
Page Range
170-175
Article Number
ACU Department
Collections
Relation URI
Source URL
Event URL
Open Access Status
License
File Access
Controlled